arrow
A

Ahmed Idbaïh

chu de nantes
H指数:75
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

MEK抑制在Erdheim–Chester疾病中实现强效且持久的应答

2026-10-070
OAAI
Gliomas with pleomorphic and pseudopapillary features (GPAP) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

具有多形性和假乳头状特征的胶质瘤(GPAP)是边界清晰的肿瘤,具有可靶向的突变、生存期延长和频繁的肿瘤易感性

2026-09-300
OAAI
CBL Variants in Suspected Histiocytic Neoplasms: A Retrospective Study of 11 Cases

<i>CBL</i> 变体在疑似组织细胞性肿瘤中的研究:11例回顾性研究

2026-09-200
PRE
The management of cancer-associated thromboembolism: Proposals from the French multidisciplinary INNOVTE CAT Working Group

癌症相关血栓栓塞的管理:法国多学科INNOVTE CAT工作组提案

2025-12-010
OAAI
CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE

IDH突变型高级别胶质瘤中的条件生存分析:临床实践中的有用工具

2025-11-010
OAAI
SONOBIRD: A PHASE 3 TRIAL OF BLOOD-BRAIN-BARRIER (BBB) OPENING WITH THE SONOCLOUD-9 IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING IV CARBOPLATIN

SONOBIRD:一项使用SONOCLOUD-9实现血脑屏障(BBB)开放的第3期临床试验,研究对象为接受静脉注射卡铂治疗的复发性胶质母细胞瘤患者

2025-11-010
OAAI
EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

EO2401多肽免疫疗法联合纳武利尤单抗及/或贝伐珠单抗治疗首次复发的胶质母细胞瘤:EOGBM1-18 / ROSALIE(NCT04116658)研究中的治疗策略优化(I/II期研究)

2025-11-010
OAAI
PROGNOSIS IMPACT OF PROCARBAZINE AND/OR VINCRISTINE DISCONTINUATION IN FIRST-LINE TREATMENT BY PCV AND RADIOTHERAPY IN WHO GRADE 3 IDH-MUTANT DIFFUSE GLIOMAS

PCB和/或VCR在PCV和放疗的一线治疗中停用对WHO 3级IDH突变型弥漫性胶质瘤预后的影响

2025-10-010
OAAI
CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE

IDH突变型高级别胶质瘤中的条件生存分析:临床实践中的有用工具

2025-10-010
OAAI
Prognostic factors in adult patients with medulloblastoma

成人髓母细胞瘤患者的预后因素

2025-09-010
PRE
Cluster analysis reveals the clinical spectrum of Erdheim-Chester disease

聚类分析揭示了Erdheim-Chester疾病的临床谱。

LEUKEMIA
IF13.4
2025-05-280
PRE
Nicotinamide metabolism reprogramming drives reversible senescence of glioblastoma cells

烟酰胺代谢重编程驱动胶质母细胞瘤细胞的可逆衰老

2025-03-210
OA
α-synuclein expression in glioblastoma restores tumor suppressor function and rescues temozolomide drug resistance

α-synuclein在胶质母细胞瘤中的表达恢复了肿瘤抑制功能并挽救了替莫唑胺耐药性

2025-03-190
OA
Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer

基于人类与共生抗原之间模拟的策略,用于开发癌症的新一代免疫疗法家族

2025-02-200
OA